界面新闻获悉,12月21日,默沙东宣布,其抗真菌药物诺科飞®(泊沙康唑)注射液剂型正式在中国境内上市,用于预防侵袭性曲霉菌和念珠菌感染及治疗侵袭性曲霉病。至此,诺科飞口服混悬液、肠溶片和注射液三类剂型均已在华获批上市。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.